Dongwha teams up with Teijin over DW1350

Published: 2008-04-03 06:57:00

Updated: 2008-04-03 06:57:00

Dongwha Pharm says on April 1 that it entered into a technology transfer agreement with Teijin Pharma under which Teijin will have exclusive rights to develop and commercialize a novel class of molecules for the treatment of osteoporosis in Japan.

The agreement includes Dongwha's novel drug D...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK